N/A N=38 Stereotactic Body Radiation Therapy (SBRT) for Lung Tumors
Lung Cancer
Primary: Disease Status — 84; 78; 55; 54 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer
Carcinoma, Non-small Cell Lung
Primary: Response Rate Defined as the Percentage of Subjects Achieving at Least 50% Tumor Volume Reduction. — 1 Participants — p=<0.01
N/A N=42 Assessment of the Effectiveness of Local Ablathermy Radio Frequency Bronchial Tumors Primitive
Malignant Non-small Cell Neoplasm of Lung Stage Ia
Primary: Local Tumor Control Rate 1 Year After Percutaneous Radiofrequency Ablation (RFA) — 5 Participants
N/A N=6 Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
Non-small Cell Lung Cancer Stage I
Primary: Examine the T-cell Receptor Profile Changes Induced in the Tumor After SABR
N/A N=44 Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung
Lung Cancer · Non Small Cell Lung Cancer · Solid Tumors
Primary: Response Rate (RR): — 38 tumors
N/A N=51 Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival at 2 Years — 69.8 percentage of participants
Phase 2 N=647 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Phase 2 N=24 Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
Primary: Percentage of Subjects With Detectable Circulating T Cells After Treatment — 16.7 Percentage of participants
N/A N=258 Navigation Endoscopy to Reach Indeterminate Lung Nodules Versus Trans-Thoracic Needle Aspiration
Lung Nodule
Primary: Diagnostic Accuracy — 94; 81 Participants — p=0.003
Phase 1 N=33 Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer
Primary: Clinical Response as Assessed Metabolically by Changes in Positron Emission Tomography (PET) Scan Between Baseline and Immediately Prior to Surgery. — 78; 64; 50; 22…
Phase 3 N=291 Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
Nonsmall Cell Lung Cancer · NSCLC
Primary: Overall Survival of Patients Treated With TTFields + Docetaxel or Immune Checkpoint Inhibitors vs. Docetaxel or Immune Checkpoint Inhibitors Alone (Superiority Analysis)…
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=40 Phase 2 Study of VGT-309 in Lung Cancer
Lung Cancer
Primary: Clinically Significant Event (CSE) — 0.425 Proportion of subjects — p=< .0001
Phase 2 N=25 Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions
Lung Cancer
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 1 Participants
Phase 2 N=59 Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
Lung Cancer
Primary: Local Control at 2 Years — 97.6 percentage of subjects — p=0.013
Phase 2 N=18 Trial of NanoPac Intratumoral Injection in Lung Cancer
Lung Cancer, Nonsmall Cell · Lung Cancer · Lung Cancer, Small Cell
Primary: Number of Participants With Treatment Emergent Adverse Events — 18 Participants
N/A N=47 A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: The Number of Patients for Whom Treatment is Feasible. — 40 Participants
N/A N=25 Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Lung Cancer
Primary: Number of Red Fluorescent [i.e., Cancer] Cells (RFCs) in Sputum From Healthy Participants — 0 number of RFCs per participant
N/A N=12 Study of Tarceva and Targretin in Stage I-II Lung Cancer
Carcinoma, Non-small-cell Lung
Primary: Number of Participants With Change in Expression Level of EGFR. — 3; 7 Participants
N/A N=256 Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
Non-small Cell Lung Cancer (NSCLC)
Primary: Evaluate Local Tumor Control With Individually-optimized Stereotactic Ablative Radiotherapy (SABR) for Lung Tumors. — 34; 70; 60; 15 lesions
N/A N=35 Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer
Lung Cancer
Primary: Boost Dose Toxicity — 5 Participants
Phase 2 N=37 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Phase 2 N=71 Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…
Phase 2 N=22 Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy
Non-small Cell Lung Cancer
Primary: Number of Participants With a Change From Baseline in Ventilation Map Using Hyperpolarized Xe-129 MR Imaging — 6 Participants — p=0.041
Phase 2 N=138 Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer
Stage III Lung Non-Small Cell Cancer AJCC v7 · Stage IIIA Lung Non-Small Cell Cancer AJCC v7 · Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Primary: Percentage of Participants Alive Without Local-regional Progression [Local-regional Progression-free (LRPF) Survival] at Two Years (NRG) — 59.5; 54.6 percentage of…
Phase 3 N=222 Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Lung Cancer
Primary: Time to Local Recurrence — NA; NA years — p=0.98
N/A N=215 BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium
Stage IV Non-small Cell Lung Cancer
Primary: The Study Outcome is Defined as the Systemic Treatment Choice. — 26; 68; 0; 99 Participants
N/A N=42 Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: 2 Year Rate of Overall Local-Regional Tumor Control Using FGD-PET-CT During Radiation Therapy(RT) — 68 percentage of patients
N/A N=131 Study of Cryoablation for Metastatic Lung Tumors
Neoplasm Metastasis
Primary: Local Tumor Control for Each Index Tumor as Measured by Imaging at Month 12 — 84.6 percentage of tumors — p=0.410
Early Phase 1 N=21 Bronchoscopic Cryo-Immunotherapy of Lung Cancer
Advanced Non-small Cell Lung Cancer
Primary: Percentage of Successful Performances Among Patients in Whom BCI is Attempted — 100 Percentage of participants